25 XP   0   0   10

MacroGenics Inc
Buy, Hold or Sell?

Let's analyse Macrogenics together

PenkeI guess you are interested in MacroGenics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of MacroGenics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about MacroGenics Inc

I send you an email if I find something interesting about MacroGenics Inc.

Quick analysis of Macrogenics (30 sec.)










What can you expect buying and holding a share of Macrogenics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$2.44
Expected worth in 1 year
$2.61
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$0.17
Return On Investment
1.2%

For what price can you sell your share?

Current Price per Share
$14.37
Expected price per share
$7.97 - $21.88
How sure are you?
50%

1. Valuation of Macrogenics (5 min.)




Live pricePrice per Share (EOD)

$14.37

Intrinsic Value Per Share

$-27.47 - $-19.38

Total Value Per Share

$-25.03 - $-16.93

2. Growth of Macrogenics (5 min.)




Is Macrogenics growing?

Current yearPrevious yearGrowGrow %
How rich?$152.6m$146.4m$10.4m6.7%

How much money is Macrogenics making?

Current yearPrevious yearGrowGrow %
Making money-$2.2m-$29.7m$27.4m1,212.8%
Net Profit Margin8.0%-204.7%--

How much money comes from the company's main activities?

3. Financial Health of Macrogenics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#298 / 1010

Most Revenue
#254 / 1010

Most Profit
#320 / 1010

Most Efficient
#121 / 1010

What can you expect buying and holding a share of Macrogenics? (5 min.)

Welcome investor! Macrogenics's management wants to use your money to grow the business. In return you get a share of Macrogenics.

What can you expect buying and holding a share of Macrogenics?

First you should know what it really means to hold a share of Macrogenics. And how you can make/lose money.

Speculation

The Price per Share of Macrogenics is $14.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Macrogenics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Macrogenics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.44. Based on the TTM, the Book Value Change Per Share is $0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.39 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Macrogenics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.73-5.1%-0.04-0.2%-0.48-3.3%-0.49-3.4%-0.37-2.6%
Usd Book Value Change Per Share-0.66-4.6%0.040.3%-0.39-2.7%-0.07-0.5%0.030.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.66-4.6%0.040.3%-0.39-2.7%-0.07-0.5%0.030.2%
Usd Price Per Share9.62-6.70-5.48-14.24-19.04-
Price to Earnings Ratio-3.28--0.16-0.71--12.32--16.27-
Price-to-Total Gains Ratio-14.54--2.47--0.80-10.93--29.72-
Price to Book Ratio3.94-2.87-2.27-3.62-5.22-
Price-to-Total Gains Ratio-14.54--2.47--0.80-10.93--29.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.37
Number of shares69
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.04-0.07
Usd Total Gains Per Share0.04-0.07
Gains per Quarter (69 shares)2.96-4.98
Gains per Year (69 shares)11.85-19.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101220-20-30
2023140-40-50
3035260-60-70
4147380-80-90
5159500-100-110
6170620-120-130
7182740-140-150
8194860-160-170
91105980-180-190
1011171100-200-210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%3.017.00.015.0%6.034.00.015.0%10.037.00.021.3%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%8.012.00.040.0%14.026.00.035.0%17.028.02.036.2%
Dividend per Share2.00.02.050.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.045.04.3%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%8.012.00.040.0%14.026.00.035.0%17.028.02.036.2%

Fundamentals of Macrogenics

About MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 14:34:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of MacroGenics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Macrogenics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • A Net Profit Margin of -416.6% means that $-4.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of MacroGenics Inc:

  • The MRQ is -416.6%. The company is making a huge loss. -2
  • The TTM is 8.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-416.6%TTM8.0%-424.5%
TTM8.0%YOY-204.7%+212.6%
TTM8.0%5Y-201.1%+209.1%
5Y-201.1%10Y-541.5%+340.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-416.6%-207.2%-209.4%
TTM8.0%-216.8%+224.8%
YOY-204.7%-282.3%+77.6%
5Y-201.1%-436.8%+235.7%
10Y-541.5%-597.3%+55.8%
1.1.2. Return on Assets

Shows how efficient Macrogenics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • -15.4% Return on Assets means that Macrogenics generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of MacroGenics Inc:

  • The MRQ is -15.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-0.6%-14.7%
TTM-0.6%YOY-12.8%+12.2%
TTM-0.6%5Y-9.4%+8.8%
5Y-9.4%10Y-7.5%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-13.3%-2.1%
TTM-0.6%-12.8%+12.2%
YOY-12.8%-11.6%-1.2%
5Y-9.4%-13.8%+4.4%
10Y-7.5%-15.6%+8.1%
1.1.3. Return on Equity

Shows how efficient Macrogenics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • -30.0% Return on Equity means Macrogenics generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of MacroGenics Inc:

  • The MRQ is -30.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-5.6%-24.4%
TTM-5.6%YOY-19.2%+13.6%
TTM-5.6%5Y-14.0%+8.4%
5Y-14.0%10Y-10.6%-3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-16.9%-13.1%
TTM-5.6%-16.1%+10.5%
YOY-19.2%-14.9%-4.3%
5Y-14.0%-19.3%+5.3%
10Y-10.6%-20.1%+9.5%

1.2. Operating Efficiency of MacroGenics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Macrogenics is operating .

  • Measures how much profit Macrogenics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • An Operating Margin of -413.4% means the company generated $-4.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of MacroGenics Inc:

  • The MRQ is -413.4%. The company is operating very inefficient. -2
  • The TTM is -318.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-413.4%TTM-318.6%-94.7%
TTM-318.6%YOY-207.0%-111.6%
TTM-318.6%5Y-280.4%-38.2%
5Y-280.4%10Y-586.3%+305.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-413.4%-298.0%-115.4%
TTM-318.6%-238.5%-80.1%
YOY-207.0%-288.4%+81.4%
5Y-280.4%-486.2%+205.8%
10Y-586.3%-628.4%+42.1%
1.2.2. Operating Ratio

Measures how efficient Macrogenics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.49 means that the operating costs are $5.49 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of MacroGenics Inc:

  • The MRQ is 5.486. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.227. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.486TTM4.227+1.258
TTM4.227YOY3.070+1.157
TTM4.2275Y4.537-0.310
5Y4.53710Y11.962-7.424
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4863.235+2.251
TTM4.2273.310+0.917
YOY3.0703.838-0.768
5Y4.5375.679-1.142
10Y11.9627.823+4.139

1.3. Liquidity of MacroGenics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Macrogenics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.48 means the company has $4.48 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of MacroGenics Inc:

  • The MRQ is 4.480. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.004. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.480TTM5.004-0.525
TTM5.004YOY3.518+1.487
TTM5.0045Y5.017-0.013
5Y5.01710Y7.325-2.307
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4803.863+0.617
TTM5.0044.169+0.835
YOY3.5185.337-1.819
5Y5.0176.122-1.105
10Y7.3256.434+0.891
1.3.2. Quick Ratio

Measures if Macrogenics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • A Quick Ratio of 6.58 means the company can pay off $6.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of MacroGenics Inc:

  • The MRQ is 6.577. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.834. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.577TTM6.834-0.257
TTM6.834YOY4.751+2.083
TTM6.8345Y6.479+0.355
5Y6.47910Y9.558-3.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5773.504+3.073
TTM6.8343.991+2.843
YOY4.7515.371-0.620
5Y6.4796.088+0.391
10Y9.5586.395+3.163

1.4. Solvency of MacroGenics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Macrogenics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Macrogenics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.49 means that Macrogenics assets are financed with 48.9% credit (debt) and the remaining percentage (100% - 48.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of MacroGenics Inc:

  • The MRQ is 0.489. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.510. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.489TTM0.510-0.021
TTM0.510YOY0.389+0.121
TTM0.5105Y0.327+0.183
5Y0.32710Y0.260+0.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4890.339+0.150
TTM0.5100.337+0.173
YOY0.3890.271+0.118
5Y0.3270.368-0.041
10Y0.2600.388-0.128
1.4.2. Debt to Equity Ratio

Measures if Macrogenics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Macrogenics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 95.5% means that company has $0.96 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of MacroGenics Inc:

  • The MRQ is 0.955. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.158. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.955TTM1.158-0.203
TTM1.158YOY0.654+0.504
TTM1.1585Y0.559+0.599
5Y0.55910Y0.403+0.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9550.392+0.563
TTM1.1580.403+0.755
YOY0.6540.335+0.319
5Y0.5590.427+0.132
10Y0.4030.461-0.058

2. Market Valuation of MacroGenics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Macrogenics generates.

  • Above 15 is considered overpriced but always compare Macrogenics to the Biotechnology industry mean.
  • A PE ratio of -3.28 means the investor is paying $-3.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of MacroGenics Inc:

  • The EOD is -4.894. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.276. Based on the earnings, the company is expensive. -2
  • The TTM is -0.156. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.894MRQ-3.276-1.618
MRQ-3.276TTM-0.156-3.120
TTM-0.156YOY0.705-0.861
TTM-0.1565Y-12.316+12.160
5Y-12.31610Y-16.267+3.951
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.894-2.300-2.594
MRQ-3.276-2.656-0.620
TTM-0.156-2.718+2.562
YOY0.705-4.145+4.850
5Y-12.316-6.258-6.058
10Y-16.267-6.315-9.952
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of MacroGenics Inc:

  • The EOD is -7.827. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.240. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.729. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.827MRQ-5.240-2.587
MRQ-5.240TTM-12.729+7.490
TTM-12.729YOY-1.226-11.503
TTM-12.7295Y-10.133-2.596
5Y-10.13310Y-9.167-0.966
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.827-2.974-4.853
MRQ-5.240-3.306-1.934
TTM-12.729-3.508-9.221
YOY-1.226-5.613+4.387
5Y-10.133-8.378-1.755
10Y-9.167-8.873-0.294
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Macrogenics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.94 means the investor is paying $3.94 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of MacroGenics Inc:

  • The EOD is 5.879. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.935. Based on the equity, the company is fair priced.
  • The TTM is 2.870. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.879MRQ3.935+1.943
MRQ3.935TTM2.870+1.066
TTM2.870YOY2.271+0.598
TTM2.8705Y3.624-0.755
5Y3.62410Y5.225-1.600
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8791.914+3.965
MRQ3.9352.116+1.819
TTM2.8702.097+0.773
YOY2.2712.881-0.610
5Y3.6243.550+0.074
10Y5.2253.936+1.289
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of MacroGenics Inc.

3.1. Institutions holding MacroGenics Inc

Institutions are holding 99.993% of the shares of MacroGenics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Bellevue Group AG16.03551.464799533131500001.5301
2023-12-31BlackRock Inc9.89250.001561403491043191.7283
2023-12-31T. Rowe Price Investment Management,Inc.9.08640.035356399941480422.6956
2023-12-31Armistice Capital, LLC7.36580.60044572000-140000-2.9711
2023-12-31Vanguard Group Inc6.94270.00094309394-105530-2.3903
2023-12-31RA Capital Management, LLC6.52980.609405307737110771085.1102
2023-12-31State Street Corporation3.50250.001217402287362167.1809
2023-12-31Geode Capital Management, LLC2.2620.00141404068840686.3688
2023-12-31Wasatch Advisors Inc.2.09050.06881297574-111960-7.9431
2023-12-31SILVERARC CAPITAL MANAGEMENT, LLC2.02783.6041258641-5517-0.4364
2023-12-31Goldman Sachs Group Inc1.99120.00111235926733868146.172
2023-12-31Dimensional Fund Advisors, Inc.1.95730.00341214900-6345-0.5196
2023-12-31Rock Springs Capital Management LP1.89910.2792117879600
2023-12-31JPMorgan Chase & Co1.82810.00111134744841748.0122
2023-12-31Acadian Asset Management LLC1.7040.03951057693-313703-22.8747
2023-12-31Millennium Management LLC1.39030.0036862965-1175923-57.6747
2023-12-31Charles Schwab Investment Management Inc1.34280.00283350081110.9827
2023-12-31Federated Hermes Inc1.29430.0192803375-126701-13.6227
2023-12-31Northern Trust Corp1.24770.001477447943090.5595
2023-12-31Renaissance Technologies Corp1.23010.01147635279837714.7902
Total 81.62046.748950662337+4014287+7.9%

3.2. Funds holding MacroGenics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BB Biotech AG Ord15.6651.863997799632000002.0877
2024-03-28SPDR® S&P Biotech ETF4.70680.57282938523370801.278
2024-02-29Vanguard Total Stock Mkt Idx Inv2.94630.0021183945000
2023-12-31T. Rowe Price Small-Cap Value2.63690.14981646300-155800-8.6455
2024-03-28iShares Russell 2000 ETF2.38370.033514882137170.0482
2023-12-31T. Rowe Price US Small-Cap Core Equity2.19830.139213724611030008.1137
2023-12-31T. Rowe Price Small-Cap Stock2.19830.139513724611030008.1137
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.46040.01691177567810.7493
2023-12-31Wasatch Ultra Growth1.42650.7152890602-96510-9.777
2023-12-31T. Rowe Price U.S. SC Value Eq Tr-Z1.26060.153378699271000.9104
2023-12-31T. Rowe Price U.S. SC Core Eq Tr-Z1.07430.13836707057060011.7646
2024-01-31Fidelity Small Cap Index0.98630.035561573996031.5843
2023-12-31Federated Hermes MDT SCC Institutional0.8820.4477550654-86610-13.5909
2023-12-31Federated Hermes MDT Small Cap Core IS0.8820.4488550654-86610-13.5909
2023-12-31T. Rowe Price Instl Small-Cap Stock0.83830.114452337611370027.7536
2024-02-29JPMorgan Small Cap Value I0.81770.6672510509-35625-6.5231
2023-12-31Vanguard Strategic Equity Inv0.7020.054143826100
2024-03-28iShares Biotechnology ETF0.69980.084343687900
2024-02-29Delaware Healthcare I0.67270.966742000000
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.65050.017440609875001.8816
Total 45.08846.759728149615+197926+0.7%

3.3. Insider Transactions

Insiders are holding 2.656% of the shares of MacroGenics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-04Jeffrey Stuart PetersSELL5139515.55
2024-02-26Jeffrey Stuart PetersSELL1612417.22
2024-02-01Ezio BonviniSELL1331615
2024-01-19Ezio BonviniSELL1331612
2023-12-20Ezio BonviniSELL1888010.08
2023-10-02Target N V BiotechBUY1500004.46
2023-09-07Target N V BiotechBUY2000005.26
2023-08-30Edward HurwitzBUY150004.91

4. Summary

4.1. Key Performance Indicators

The key performance indicators of MacroGenics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6630.042-1661%-0.391-41%-0.072-89%0.030-2345%
Book Value Per Share--2.4442.512-3%2.345+4%3.636-33%3.770-35%
Current Ratio--4.4805.004-10%3.518+27%5.017-11%7.325-39%
Debt To Asset Ratio--0.4890.510-4%0.389+26%0.327+49%0.260+88%
Debt To Equity Ratio--0.9551.158-18%0.654+46%0.559+71%0.403+137%
Dividend Per Share--0.0010.000+100%-+100%0.000+900%0.000+1900%
Eps---0.734-0.035-95%-0.480-35%-0.490-33%-0.369-50%
Free Cash Flow Per Share---0.459-0.320-30%-0.363-21%-0.462+1%-0.354-23%
Free Cash Flow To Equity Per Share---0.4550.282-261%-0.356-22%-0.006-99%0.044-1144%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---19.377--------
Intrinsic Value_10Y_min---27.472--------
Intrinsic Value_1Y_max---1.495--------
Intrinsic Value_1Y_min---1.901--------
Intrinsic Value_3Y_max---4.832--------
Intrinsic Value_3Y_min---6.483--------
Intrinsic Value_5Y_max---8.579--------
Intrinsic Value_5Y_min---11.875--------
Market Cap897147840.000+33%600595840.000418294400.000+44%342283440.000+75%889062896.000-32%1188861360.000-49%
Net Profit Margin---4.1660.080-5337%-2.047-51%-2.011-52%-5.415+30%
Operating Margin---4.134-3.186-23%-2.070-50%-2.804-32%-5.863+42%
Operating Ratio--5.4864.227+30%3.070+79%4.537+21%11.962-54%
Pb Ratio5.879+33%3.9352.870+37%2.271+73%3.624+9%5.225-25%
Pe Ratio-4.894-49%-3.276-0.156-95%0.705-565%-12.316+276%-16.267+397%
Price Per Share14.370+33%9.6206.700+44%5.483+75%14.241-32%19.043-49%
Price To Free Cash Flow Ratio-7.827-49%-5.240-12.729+143%-1.226-77%-10.133+93%-9.167+75%
Price To Total Gains Ratio-21.719-49%-14.539-2.471-83%-0.798-95%10.933-233%-29.715+104%
Quick Ratio--6.5776.834-4%4.751+38%6.479+2%9.558-31%
Return On Assets---0.154-0.006-96%-0.128-17%-0.094-39%-0.075-51%
Return On Equity---0.300-0.056-81%-0.192-36%-0.140-53%-0.106-65%
Total Gains Per Share---0.6620.043-1642%-0.391-41%-0.072-89%0.030-2338%
Usd Book Value--152613000.000156851250.000-3%146416500.000+4%227021150.000-33%235398654.700-35%
Usd Book Value Change Per Share---0.6630.042-1661%-0.391-41%-0.072-89%0.030-2345%
Usd Book Value Per Share--2.4442.512-3%2.345+4%3.636-33%3.770-35%
Usd Dividend Per Share--0.0010.000+100%-+100%0.000+900%0.000+1900%
Usd Eps---0.734-0.035-95%-0.480-35%-0.490-33%-0.369-50%
Usd Free Cash Flow---28657000.000-19992250.000-30%-22645500.000-21%-28847250.000+1%-22109500.000-23%
Usd Free Cash Flow Per Share---0.459-0.320-30%-0.363-21%-0.462+1%-0.354-23%
Usd Free Cash Flow To Equity Per Share---0.4550.282-261%-0.356-22%-0.006-99%0.044-1144%
Usd Market Cap897147840.000+33%600595840.000418294400.000+44%342283440.000+75%889062896.000-32%1188861360.000-49%
Usd Price Per Share14.370+33%9.6206.700+44%5.483+75%14.241-32%19.043-49%
Usd Profit---45833000.000-2264500.000-95%-29729250.000-35%-30582000.000-33%-22992483.375-50%
Usd Revenue--11003000.00014687250.000-25%37397500.000-71%22188500.000-50%22540766.975-51%
Usd Total Gains Per Share---0.6620.043-1642%-0.391-41%-0.072-89%0.030-2338%
 EOD+5 -3MRQTTM+8 -27YOY+12 -235Y+7 -2810Y+8 -27

4.2. Fundamental Score

Let's check the fundamental score of MacroGenics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.894
Price to Book Ratio (EOD)Between0-15.879
Net Profit Margin (MRQ)Greater than0-4.166
Operating Margin (MRQ)Greater than0-4.134
Quick Ratio (MRQ)Greater than16.577
Current Ratio (MRQ)Greater than14.480
Debt to Asset Ratio (MRQ)Less than10.489
Debt to Equity Ratio (MRQ)Less than10.955
Return on Equity (MRQ)Greater than0.15-0.300
Return on Assets (MRQ)Greater than0.05-0.154
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of MacroGenics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.444
Ma 20Greater thanMa 5016.280
Ma 50Greater thanMa 10016.780
Ma 100Greater thanMa 20014.166
OpenGreater thanClose14.930
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Depreciation and Amortization  3,231-2,1581,073102,132103,205-101,2551,950-108,178-106,228
Cost of Revenue  1,7911,7323,523-2,3461,177-1,09285-4,251-4,166



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets298,418
Total Liabilities145,805
Total Stockholder Equity152,613
 As reported
Total Liabilities 145,805
Total Stockholder Equity+ 152,613
Total Assets = 298,418

Assets

Total Assets298,418
Total Current Assets251,339
Long-term Assets47,079
Total Current Assets
Cash And Cash Equivalents 100,956
Short-term Investments 128,849
Net Receivables 10,367
Inventory 1,221
Other Current Assets 9,946
Total Current Assets  (as reported)251,339
Total Current Assets  (calculated)251,339
+/-0
Long-term Assets
Property Plant Equipment 45,693
Long-term Assets Other 1,386
Long-term Assets  (as reported)47,079
Long-term Assets  (calculated)47,079
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities56,108
Long-term Liabilities89,697
Total Stockholder Equity152,613
Total Current Liabilities
Short-term Debt 3,775
Accounts payable 6,443
Other Current Liabilities 24,239
Total Current Liabilities  (as reported)56,108
Total Current Liabilities  (calculated)34,457
+/- 21,651
Long-term Liabilities
Capital Lease Obligations 33,971
Long-term Liabilities Other 258
Long-term Liabilities  (as reported)89,697
Long-term Liabilities  (calculated)34,229
+/- 55,468
Total Stockholder Equity
Common Stock621
Retained Earnings -1,102,752
Accumulated Other Comprehensive Income -6
Other Stockholders Equity 1,254,750
Total Stockholder Equity (as reported)152,613
Total Stockholder Equity (calculated)152,613
+/-0
Other
Capital Stock621
Cash and Short Term Investments 229,805
Common Stock Shares Outstanding 61,929
Current Deferred Revenue21,651
Liabilities and Stockholders Equity 298,418
Net Debt -66,985
Net Invested Capital 152,613
Net Working Capital 195,231
Property Plant and Equipment Gross 134,087
Short Long Term Debt Total 33,971



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
62,681
0
53,747
0
42,183
41,976
125,782
210,173
205,720
193,625
173,886
278,070
254,203
384,089
359,269
325,657
368,850
339,864
311,263
274,721
274,846
241,845
373,883
326,078
386,891
355,356
332,130
414,638
383,677
351,451
312,501
265,413
327,592
374,380
378,743
435,445
425,911
392,160
335,245
271,445
218,043
195,347
280,468
343,498
305,653
339,972
298,418
298,418339,972305,653343,498280,468195,347218,043271,445335,245392,160425,911435,445378,743374,380327,592265,413312,501351,451383,677414,638332,130355,356386,891326,078373,883241,845274,846274,721311,263339,864368,850325,657359,269384,089254,203278,070173,886193,625205,720210,173125,78241,97642,183053,747062,681
   > Total Current Assets 
0
0
49,927
0
38,005
36,954
119,457
202,404
198,759
186,959
164,737
268,470
242,427
370,495
342,384
309,266
348,444
316,286
283,947
251,007
250,114
209,466
322,298
271,039
322,054
285,642
269,124
335,033
287,597
276,233
239,785
195,285
260,196
310,068
312,594
374,719
366,996
334,698
279,560
218,201
167,633
147,812
222,180
288,943
240,347
291,319
251,339
251,339291,319240,347288,943222,180147,812167,633218,201279,560334,698366,996374,719312,594310,068260,196195,285239,785276,233287,597335,033269,124285,642322,054271,039322,298209,466250,114251,007283,947316,286348,444309,266342,384370,495242,427268,470164,737186,959198,759202,404119,45736,95438,005049,92700
       Cash And Cash Equivalents 
55,219
0
47,743
0
33,781
33,569
116,481
198,722
194,014
179,191
157,591
263,134
235,027
365,767
196,172
151,952
62,267
109,901
84,098
40,518
116,627
90,884
211,727
200,448
238,661
201,807
220,128
238,641
180,316
156,593
126,472
93,056
196,532
201,637
181,131
218,496
188,970
190,531
123,469
47,328
21,469
83,993
108,884
224,264
108,758
89,898
100,956
100,95689,898108,758224,264108,88483,99321,46947,328123,469190,531188,970218,496181,131201,637196,53293,056126,472156,593180,316238,641220,128201,807238,661200,448211,72790,884116,62740,51884,098109,90162,267151,952196,172365,767235,027263,134157,591179,191194,014198,722116,48133,56933,781047,743055,219
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
142,877
152,496
203,357
201,222
192,898
202,585
127,033
112,763
93,394
59,633
62,233
58,336
12,735
81,750
91,820
97,823
89,284
77,793
36,267
79,022
91,400
124,681
108,346
108,367
120,147
136,658
112,271
39,623
45,462
17,392
131,589
166,534
128,849
128,849166,534131,58917,39245,46239,623112,271136,658120,147108,367108,346124,68191,40079,02236,26777,79389,28497,82391,82081,75012,73558,33662,23359,63393,394112,763127,033202,585192,898201,222203,357152,496142,87700000000000000
       Net Receivables 
0
0
2,046
0
4,153
2,281
2,004
1,746
2,645
5,315
2,935
1,719
4,334
2,744
1,224
2,512
78,375
3,008
2,764
2,093
1,991
2,194
13,643
7,281
17,836
20,970
29,583
6,115
5,613
9,503
12,744
11,806
19,205
18,777
23,081
7,148
45,248
13,759
10,386
14,905
18,385
13,837
56,222
36,160
6,410
25,311
10,367
10,36725,3116,41036,16056,22213,83718,38514,90510,38613,75945,2487,14823,08118,77719,20511,80612,7449,5035,6136,11529,58320,97017,8367,28113,6432,1941,9912,0932,7643,00878,3752,5121,2242,7444,3341,7192,9355,3152,6451,7462,0042,2814,15302,04600
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,172
6,476
3,979
4,388
4,598
2,949
1,086
1,451
1,409
1,443
1,066
1,221
1,2211,0661,4431,4091,4511,0862,9494,5984,3883,9796,4766,17200000000000000000000000000000000000
   > Long-term Assets 
0
0
3,820
0
4,178
5,022
6,325
7,769
6,961
6,666
9,149
9,600
11,776
13,594
16,885
16,391
20,406
23,578
27,316
23,714
24,732
32,379
51,585
55,039
64,837
69,714
63,006
79,605
96,080
75,218
72,716
70,128
67,396
64,312
66,149
60,726
58,915
57,462
55,685
53,244
50,410
47,535
58,288
54,555
65,306
48,653
47,079
47,07948,65365,30654,55558,28847,53550,41053,24455,68557,46258,91560,72666,14964,31267,39670,12872,71675,21896,08079,60563,00669,71464,83755,03951,58532,37924,73223,71427,31623,57820,40616,39116,88513,59411,7769,6009,1496,6666,9617,7696,3255,0224,17803,82000
       Property Plant Equipment 
3,288
0
3,268
0
3,626
4,470
5,035
5,084
5,442
5,633
6,785
7,236
9,412
11,530
14,841
14,347
18,294
18,473
17,961
17,376
23,179
30,838
49,983
53,443
57,491
58,649
56,712
54,818
52,295
49,966
48,211
46,318
43,887
41,423
42,225
40,475
39,395
38,684
37,676
36,034
34,022
31,993
56,910
53,177
49,592
47,266
45,693
45,69347,26649,59253,17756,91031,99334,02236,03437,67638,68439,39540,47542,22541,42343,88746,31848,21149,96652,29554,81856,71258,64957,49153,44349,98330,83823,17917,37617,96118,47318,29414,34714,84111,5309,4127,2366,7855,6335,4425,0845,0354,4703,62603,26803,288
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,001
7,986
4,978
0
0
0
0
6,130
6,130
1,890
2,708
22,356
0
1,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,900022,3562,7081,8906,1306,13000004,9787,9863,00100000000000000000
       Long-term Assets Other 
0
0
552
0
552
552
1,290
2,684
1,519
1,033
2,364
2,364
2,364
2,064
2,044
2,044
2,112
2,104
1,369
1,360
1,553
1,541
1,602
1,596
7,346
11,065
6,294
24,787
43,785
25,252
24,505
23,810
23,509
22,889
23,924
20,251
19,520
18,778
18,009
17,210
16,388
15,542
-7,665
1,378
15,714
1,387
1,386
1,3861,38715,7141,378-7,66515,54216,38817,21018,00918,77819,52020,25123,92422,88923,50923,81024,50525,25243,78524,7876,29411,0657,3461,5961,6021,5411,5531,3601,3692,1042,1122,0442,0442,0642,3642,3642,3641,0331,5192,6841,290552552055200
> Total Liabilities 
80,165
0
61,984
0
53,113
46,024
46,868
56,954
63,741
54,537
52,600
47,077
42,514
44,763
45,932
39,402
38,874
39,762
42,512
40,083
43,498
52,380
74,645
78,802
74,855
72,712
89,253
94,021
89,226
96,253
81,873
74,840
79,808
82,795
82,859
84,914
106,866
100,722
95,627
93,231
75,562
72,389
138,455
234,230
134,109
145,992
145,805
145,805145,992134,109234,230138,45572,38975,56293,23195,627100,722106,86684,91482,85982,79579,80874,84081,87396,25389,22694,02189,25372,71274,85578,80274,64552,38043,49840,08342,51239,76238,87439,40245,93244,76342,51447,07752,60054,53763,74156,95446,86846,02453,113061,984080,165
   > Total Current Liabilities 
44,289
0
29,728
0
28,075
25,266
28,822
29,385
29,872
25,988
27,094
24,128
23,847
22,387
23,288
17,807
19,529
22,052
27,302
26,552
29,889
32,438
49,755
49,956
48,027
48,025
59,940
51,771
49,535
57,634
45,167
39,610
45,894
50,121
50,673
53,043
69,924
68,864
74,578
67,097
50,877
50,046
48,611
45,614
68,209
51,291
56,108
56,10851,29168,20945,61448,61150,04650,87767,09774,57868,86469,92453,04350,67350,12145,89439,61045,16757,63449,53551,77159,94048,02548,02749,95649,75532,43829,88926,55227,30222,05219,52917,80723,28822,38723,84724,12827,09425,98829,87229,38528,82225,26628,075029,728044,289
       Short-term Debt 
0
0
1,237
0
941
1,229,454,000
1,438,742
1,487,854,000
1,538
1,589
1,642
1,696
1,898
1,958
2,020
2,083
1,459
1,525
1,593
1,511
1,120
715
298
31,394
38,086
39,487
34,039
3,734
3,644
2,956
3,020
3,088
3,386
3,808
3,988
4,212
4,367
4,521
4,677
4,837
4,940
5,021
4,726
4,418
4,161
3,926
3,775
3,7753,9264,1614,4184,7265,0214,9404,8374,6774,5214,3674,2123,9883,8083,3863,0883,0202,9563,6443,73434,03939,48738,08631,3942987151,1201,5111,5931,5251,4592,0832,0201,9581,8981,6961,6421,5891,5381,487,854,0001,438,7421,229,454,00094101,23700
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,734
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000003,734000000000000000000000000000
       Accounts payable 
11,051
0
3,739
0
2,119
1,798
3,169
5,133
3,977
4,388
1,669
1,444
1,853
2,541
2,967
1,118
1,150
1,374
3,995
1,515
2,088
1,680
2,451
10,266
1,767
986
4,005
925
857
2,543
4,308
1,956
2,766
4,380
8,031
10,346
9,818
6,170
15,500
3,731
2,609
4,619
4,899
3,759
3,795
3,303
6,443
6,4433,3033,7953,7594,8994,6192,6093,73115,5006,1709,81810,3468,0314,3802,7661,9564,3082,5438579254,0059861,76710,2662,4511,6802,0881,5153,9951,3741,1501,1182,9672,5411,8531,4441,6694,3883,9775,1333,1691,7982,11903,739011,051
       Other Current Liabilities 
33,238
0
629
0
1,025
-1,229,451,831
-1,433,357
-1,487,849,414
3,673
4,394
9,535
8,606
9,910
10,725
12,435
9,687
12,342
15,370
17,453
19,265
23,479
26,841
39,804
175
175
175
175
29,027
30,585
28,564
27,139
25,060
30,475
32,674
34,198
34,965
39,174
41,859
33,755
32,967
31,763
33,321
28,998
-29,818
-7,956
-38,782
24,239
24,239-38,782-7,956-29,81828,99833,32131,76332,96733,75541,85939,17434,96534,19832,67430,47525,06027,13928,56430,58529,02717517517517539,80426,84123,47919,26517,45315,37012,3429,68712,43510,7259,9108,6069,5354,3943,673-1,487,849,414-1,433,357-1,229,451,8311,0250629033,238
   > Long-term Liabilities 
0
0
32,256
0
25,038
20,759
18,046
27,569
33,869
28,549
25,506
22,949
18,667
22,376
22,644
21,595
19,345
17,710
15,210
13,531
13,609
19,942
24,890
28,846
26,828
24,687
29,313
42,250
39,691
38,619
36,706
35,230
33,914
32,674
32,186
31,871
36,942
31,858
21,049
26,134
24,685
22,343
89,844
188,616
65,900
94,701
89,697
89,69794,70165,900188,61689,84422,34324,68526,13421,04931,85836,94231,87132,18632,67433,91435,23036,70638,61939,69142,25029,31324,68726,82828,84624,89019,94213,60913,53115,21017,71019,34521,59522,64422,37618,66722,94925,50628,54933,86927,56918,04620,75925,038032,25600
       Capital Lease Obligations Min Short Term Debt
0
0
-1,237
0
-941
-1,229,454,000
-1,438,742
-1,487,854,000
-1,538
-1,589
-1,642
-1,696
-1,898
-1,958
-2,020
-2,083
-1,459
-1,525
-1,593
-1,511
-1,120
-715
-298
-31,394
-38,086
-39,487
-34,039
25,043
24,278
28,582
27,553
26,615
25,653
24,651
25,260
24,353
23,208
22,025
20,791
19,512
18,264
17,001
30,106
30,130
30,158
30,183
30,196
30,19630,18330,15830,13030,10617,00118,26419,51220,79122,02523,20824,35325,26024,65125,65326,61527,55328,58224,27825,043-34,039-39,487-38,086-31,394-298-715-1,120-1,511-1,593-1,525-1,459-2,083-2,020-1,958-1,898-1,696-1,642-1,589-1,538-1,487,854,000-1,438,742-1,229,454,000-9410-1,23700
       Long-term Liabilities Other 
0
0
0
0
0
9,057
8,006
7,610
7,204
6,789
6,364
5,914
3,725
3,215
2,693
2,869
1,847
1,442
298
0
0
0
0
0
0
0
0
42,250
39,691
38,619
0
35,230
33,914
32,674
25,260
31,871
258
31,858
258
26,134
258
22,343
258
188,616
88,954
258
258
25825888,954188,61625822,34325826,13425831,85825831,87125,26032,67433,91435,230038,61939,69142,250000000002981,4421,8472,8692,6933,2153,7255,9146,3646,7897,2047,6108,0069,05700000
       Deferred Long Term Liability 
0
0
0
0
0
11,701
10,040
19,959
26,665
21,760
19,142
17,035
14,942
19,161
19,951
18,726
17,498
16,268
14,912
13,531
13,609
19,942
24,890
28,846
26,828
24,687
29,313
0
0
0
0
0
0
0
6,926
0
0
0
0
0
0
0
59,480
0
0
0
0
000059,48000000006,926000000029,31324,68726,82828,84624,89019,94213,60913,53114,91216,26817,49818,72619,95119,16114,94217,03519,14221,76026,66519,95910,04011,70100000
> Total Stockholder Equity
0
0
-8,237
0
-10,930
-4,048
78,914
153,219
141,979
139,088
121,286
230,993
211,689
339,326
313,337
286,255
329,976
300,102
268,751
234,638
231,348
189,465
299,238
247,276
312,036
282,644
242,877
320,617
294,451
255,198
230,628
190,573
247,784
291,585
295,884
350,531
319,045
291,438
239,618
178,214
142,481
122,958
142,013
109,268
171,544
193,980
152,613
152,613193,980171,544109,268142,013122,958142,481178,214239,618291,438319,045350,531295,884291,585247,784190,573230,628255,198294,451320,617242,877282,644312,036247,276299,238189,465231,348234,638268,751300,102329,976286,255313,337339,326211,689230,993121,286139,088141,979153,21978,914-4,048-10,9300-8,23700
   Common Stock
10
0
11
0
190
21
252
275
277
278
280
300
301
342
343
345
347
348
349
350
367
368
369
370
422
422
424
488
489
489
490
492
534
562
562
600
601
613
613
613
615
615
617
618
619
620
621
62162061961861761561561361361360160056256253449249048948948842442242237036936836735034934834734534334230130028027827727525221190011010
   Retained Earnings Total Equity00-1,074,234-1,131,703-1,093,694-1,106,496-1,081,683-1,040,379-973,936-915,914-863,028-823,093-771,821-769,734-733,691-686,8060-611,686-567,055-535,288-490,271-445,627-411,599-368,355-312,340-418,067-371,024-330,370-292,714-257,931-224,085-264,549-234,186-205,735-190,293-168,917-214,046-195,028-191,100-178,842-175,733-172,52800000
   Accumulated Other Comprehensive Income 
0
0
-14,339
0
-14,857
-15,174
-15,533
-15,533
0
0
-17,355
-17,355
0
0
-5
52
59
18
-82
-108
-80
-27
-61
-23
17
0
-3
0
34
23
16
72
17
2
-7
11
1
-3
-61
-283
-326
-113
-5
8
-72
-34
-6
-6-34-728-5-113-326-283-61-3111-7217721623340-3017-23-61-27-80-108-82185952-500-17,355-17,35500-15,533-15,533-15,174-14,8570-14,33900
   Capital Surplus 
0
0
0
0
0
165,569
254,454
331,786
332,802
333,838
335,071
399,629
401,681
544,719
547,185
550,407
553,655
557,667
561,198
564,766
602,085
607,191
611,270
615,284
723,196
727,849
732,727
855,417
860,983
866,372
872,204
876,815
980,924
1,060,755
1,067,150
1,173,013
1,181,471
1,206,742
1,213,002
1,218,263
1,223,875
1,228,952
1,235,095
1,240,345
1,245,231
0
0
001,245,2311,240,3451,235,0951,228,9521,223,8751,218,2631,213,0021,206,7421,181,4711,173,0131,067,1501,060,755980,924876,815872,204866,372860,983855,417732,727727,849723,196615,284611,270607,191602,085564,766561,198557,667553,655550,407547,185544,719401,681399,629335,071333,838332,802331,786254,454165,56900000
   Treasury Stock00000000000000000000000000000000000-19-19000-58-58-580-580-58
   Other Stockholders Equity 
0
0
178,616
0
182,870
180,686
269,929
331,786
332,802
333,838
352,407
399,610
401,681
544,719
567,370
550,459
553,714
557,685
586,939
564,658
602,005
607,164
640,128
615,261
723,213
727,849
770,659
855,417
861,017
866,395
921,945
876,887
980,924
1,060,755
1,067,150
1,173,013
1,181,471
1,206,742
1,213,002
1,218,263
1,223,875
1,228,952
1,235,095
1,240,345
1,245,231
1,250,074
1,254,750
1,254,7501,250,0741,245,2311,240,3451,235,0951,228,9521,223,8751,218,2631,213,0021,206,7421,181,4711,173,0131,067,1501,060,755980,924876,887921,945866,395861,017855,417770,659727,849723,213615,261640,128607,164602,005564,658586,939557,685553,714550,459567,370544,719401,681399,610352,407333,838332,802331,786269,929180,686182,8700178,61600



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue58,749
Cost of Revenue-619
Gross Profit58,13058,130
 
Operating Income (+$)
Gross Profit58,130
Operating Expense-226,374
Operating Income-168,244-168,244
 
Operating Expense (+$)
Research Development166,583
Selling General Administrative52,188
Selling And Marketing Expenses0
Operating Expense226,374218,771
 
Net Interest Income (+$)
Interest Income9,686
Interest Expense-1,430
Other Finance Cost-0
Net Interest Income8,256
 
Pretax Income (+$)
Operating Income-168,244
Net Interest Income8,256
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-9,058-327,430
EBIT - interestExpense = -1,430
-9,058
-7,628
Interest Expense1,430
Earnings Before Interest and Taxes (EBIT)0-7,628
Earnings Before Interest and Taxes (EBITDA)-168,244
 
After tax Income (+$)
Income Before Tax-9,058
Tax Provision-0
Net Income From Continuing Ops-9,058-9,058
Net Income-9,058
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses226,993
Total Other Income/Expenses Net159,186-8,256
 

Technical Analysis of Macrogenics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Macrogenics. The general trend of Macrogenics is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Macrogenics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of MacroGenics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 19.54 < 21.88.

The bearish price targets are: 12.82 > 9.33 > 7.97.

Tweet this
MacroGenics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of MacroGenics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

MacroGenics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of MacroGenics Inc. The current macd is -0.23613362.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Macrogenics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Macrogenics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Macrogenics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
MacroGenics Inc Daily Moving Average Convergence/Divergence (MACD) ChartMacroGenics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of MacroGenics Inc. The current adx is 19.00.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Macrogenics shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
MacroGenics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of MacroGenics Inc. The current sar is 18.93.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
MacroGenics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of MacroGenics Inc. The current rsi is 38.44. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
MacroGenics Inc Daily Relative Strength Index (RSI) ChartMacroGenics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of MacroGenics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Macrogenics price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
MacroGenics Inc Daily Stochastic Oscillator ChartMacroGenics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of MacroGenics Inc. The current cci is -79.85095358.

MacroGenics Inc Daily Commodity Channel Index (CCI) ChartMacroGenics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of MacroGenics Inc. The current cmo is -35.07687527.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
MacroGenics Inc Daily Chande Momentum Oscillator (CMO) ChartMacroGenics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of MacroGenics Inc. The current willr is -95.5644267.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
MacroGenics Inc Daily Williams %R ChartMacroGenics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of MacroGenics Inc.

MacroGenics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of MacroGenics Inc. The current atr is 1.17034741.

MacroGenics Inc Daily Average True Range (ATR) ChartMacroGenics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of MacroGenics Inc. The current obv is 51,138,175.

MacroGenics Inc Daily On-Balance Volume (OBV) ChartMacroGenics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of MacroGenics Inc. The current mfi is 40.85.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
MacroGenics Inc Daily Money Flow Index (MFI) ChartMacroGenics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for MacroGenics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

MacroGenics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of MacroGenics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.444
Ma 20Greater thanMa 5016.280
Ma 50Greater thanMa 10016.780
Ma 100Greater thanMa 20014.166
OpenGreater thanClose14.930
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Macrogenics with someone you think should read this too:
  • Are you bullish or bearish on Macrogenics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Macrogenics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about MacroGenics Inc

I send you an email if I find something interesting about MacroGenics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about MacroGenics Inc.

Receive notifications about MacroGenics Inc in your mailbox!